Tag: C-Path
-
Critical Path Institute Launches New Approach Methodologies Developer Coalition to Advance Human-Relevant Tools for Drug Development
Global coalition unites NAMs developers to accelerate validation, qualification, and regulatory adoption of human-relevant methodologies, reducing reliance on animal models and improving the efficiency of drug development. TUCSON, Ariz., and AMSTERDAM, May 19, 2026 — Critical Path Institute® (C-Path) today announced the launch of the New Approach Methodologies Developer Coalition (NAMs-DC), a precompetitive, public-private initiative bringing…
-
C-Path Welcomes Rare Disease Advocacy Leader Ronald J. Bartek to Board of Directors
TUCSON, Ariz., Sept. 8, 2025 ⎯ Critical Path Institute® (C-Path) today announced the election of Ronald J. Bartek to its Board of Directors. Bartek’s experience spans leadership in rare disease advocacy and public service. The appointment comes as C-Path continues to expand its leadership role in accelerating global drug development through data-driven, scientific solutions, based on…
-
2025 C-Path Global Impact Conference
We’re excited to announce that registration is now open for the 2025 Critical Path Institute® (C-Path) Global Impact Conference (CGIC), taking place September 9–11 at the Washington Marriott at Metro Center in downtown Washington, D.C. The 2025 Critical Path Institute® (C-Path) Global Impact Conference (CGIC) is a premier gathering of leaders, innovators, and advocates shaping…
-
C-Path’s Translational Therapeutics Accelerator Announces New Grant Award for Drug Development Project in Type 1 Diabetes
TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D). Kyle Apley, Ph.D., Cory Berkland, Ph.D., and Peggy Kendall M.D., at Washington University in St. Louis, have received this TRxA award to advance their…
-
Critical Path Institute Celebrates 20 Years of Advancing Drug Development through Innovation and Collaboration
TUCSON, Ariz., May 8, 2025 — The year 2025 marks a historic milestone for Critical Path Institute® (C-Path), as the organization celebrates 20 years of transforming the landscape of drug development through collaboration, regulatory science, and next-generation strategies. Founded in 2005 by Raymond Woosley, M.D., Ph.D., with the support of leaders across multiple sectors in the…
-
C-Path’s Predictive Safety Testing Consortium Advances a Transformative Test to Detect Drug Induced Liver Injury
Serum Glutamate Dehydrogenase Activity Enables Sensitive and Specific Diagnosis of Hepatocellular Injury in Humans TUCSON, Ariz., March 27, 2025 – Researchers from Critical Path Institute’s® (C-Path) Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for detecting liver injury, supporting clearer decision-making. Currently, alanine aminotransferase and aspartate aminotransferase (ALT and AST)…
-
C-Path Announces Jennifer Kendra as New Vice President of Strategic Relationships
New Leadership to Drive Expansion of Collaborative Initiatives and Fundraising Strategies at C-Path TUCSON, Ariz., January 23, 2025 — Critical Path Institute® (C-Path) today announced the appointment of Jennifer Kendra as the new Vice President of Strategic Relationships. With a robust career spanning over two decades in strategic planning, partnership development, and executive leadership, Kendra is…
